GATA2 Deficiency: Early Identification for Improved Clinical Outcomes

Clin J Oncol Nurs. 2019 Aug 1;23(4):417-422. doi: 10.1188/19.CJON.417-422.

Abstract

Background: Patients with GATA2 deficiency present with nontuberculous mycobacterial infections, severe viral infections (particularly refractory human papillomavirus disease), lymphedema, myelodysplastic syndrome (MDS), and acute myeloid leukemia. Patients with GATA2 deficiency who undergo allogeneic hematopoietic stem cell transplantation prior to the development of life-threatening infections or cytogenetic abnormalities may have optimal clinical outcomes.

Objectives: The aim of this article is to determine ways in which oncology nurses can identify GATA2 deficiency in patients early and optimize treatment decisions.

Methods: A case study is presented of a 33-year-old man with recurrent infections and MDS and his two sons, all of whom were found to have the same GATA2 mutation.

Findings: Oncology nurses play an important role in early detection and identification by interviewing patients and obtaining a complete and thorough family history.

Keywords: GATA2 deficiency; acute myeloid leukemia; myelodysplastic syndrome.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Female
  • GATA2 Transcription Factor / deficiency*
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Male
  • Myelodysplastic Syndromes / nursing
  • Myelodysplastic Syndromes / therapy*
  • Oncology Nursing
  • Treatment Outcome*

Substances

  • GATA2 Transcription Factor
  • GATA2 protein, human